

## Regimen Reference Order – MYEL – bortezomib (maintenance)

ARIA: MYEL – [bortezomib (maintenance)]

Planned Course: Every 14 days for 2 years (1 cycle = 84 days)

Indication for Use: Multiple Myeloma

CVAD: At Provider's Discretion

### ***Proceed with treatment if:***

***ANC equal to or greater than  $0.5 \times 10^9/L$  AND Platelets equal to or greater than  $30 \times 10^9/L$***

❖ **Contact Hematologist if parameters not met**

***Note: Hepatitis B serology results must be reviewed in accordance with CCMB Policy Hepatitis B Monitoring for Oncology and Hematology Patients***

## SEQUENCE OF MEDICATION ADMINISTRATION

### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

### Treatment Regimen – MYEL – bortezomib (maintenance)

Drug	Dose	CCMB Administration Guideline
<b>Cycles 1 to 8</b>		
bortezomib	1.3 mg/m <sup>2</sup>	Subcutaneous once every 2 weeks on <b>Days 1, 15, 29, 43, 57 and 71</b>
<b>Cycle 9</b>		
bortezomib	1.3 mg/m <sup>2</sup>	Subcutaneous once every 2 weeks on <b>Days 1, 15, 29 and 43</b>

**In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'**

## REQUIRED MONITORING

### Hepatitis B serology

- Hepatitis B surface antigen and Hepatitis B core antibody (drawn within preceding 5 years)

### Cycles 1 to 8

#### Days 1, 29 and 57

- CBC, reticulocyte count, serum creatinine, calcium, albumin, random glucose and liver enzymes as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

### Cycle 9

#### Days 1 and 29

- CBC, reticulocyte count, serum creatinine, calcium, albumin, random glucose and liver enzymes as per Physician Orders
- Serum Protein Electrophoresis (SPEP)/Free Light Chain Ratio (FLCH) (response assessment)

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
valACYclovir	500 mg	Orally once daily
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

### DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Remind patient to take valACYclovir (shingles prophylaxis) at home. valACYclovir treatment continues for 4 weeks after the last dose of bortezomib
- bortezomib has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
- Advise patient to avoid green tea to prevent interactions with bortezomib
- Avoid grapefruit and grapefruit juice, Seville oranges (i.e. orange marmalade) and starfruit
- Reinforce safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

### ADDITIONAL INFORMATION

- Due to the risk of reactivation of Hepatitis B virus (HBV) while on this treatment regimen, prescriber must adhere to CCMB Policy **Hepatitis B Monitoring for Oncology and Hematology Patients** for ordering and interpreting HBV serology and prescribing antiviral prophylaxis
- All patients should be considered for bisphosphonate therapy
- bortezomib may cause peripheral neuropathy; dose modification may be required